Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITRINO: Encelimab +/- Dostarlimab in Advanced Solid Tumors
NCT03250832Phase 1Completed
- Start
- Aug 2017
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of encelimab in solid tumor and colorectal cancer (CRC) (6 arms). Primary endpoints: Dose Limiting Toxicity at 30 days, Serious Adverse Events, Treatment-emergent AEs, and Immune-related AEs at 51 months and 3 more. Started Aug 2017; status: completed.
02
Drugs
encelimab
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03250832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250832.